FLT3 D835Y

CI-VAR-00000579Explore in graph →NP_004110.2:p.Asp835TyrNM_004119.3:c.2503G>TClinVar 16276 CIViC 3011 rs121913488

Curated evidence

Evidence by cancer (16 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–16 of 16 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia14
FLT3 D835Y	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID12617 Cos7 cells transfected with mutant FLT3 D835Y cDNA demonstrated FLT3 ligand-independent tyrosine phosphorylation. 32D cells stably expressing mutant FLT3 D835Y proliferated without either IL-3 or reco… (full text at CIViC) PMID 11290608 · Yamamoto et al., 2001 · Open in CIViC	civic
FLT3 D835Y	(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID12812 Ba/F3 cells expressing FLT3 D835Y were stably transfected, cultured for 48 hours and then cell viability was analyzed. Wild-type FLT3 cells grown with IL-3 or in the absence of IL-3 served as positive… (full text at CIViC) PMID 29372308 · Marhäll et al., 2018 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm2
FLT3 D835Y	Gilteritinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID8106 Gilteritinib inhibited the cell growth of Ba/F3 cells expressing D835Y (IC50 1.6 nM; 95% CI: 1.1–2.4 nM) compared to controls (IC50 420nM; 95% CI: 350–500 nM). Additionally, immunoblots showed gliteri… (full text at CIViC) PMID 28516360 · Mori et al., 2017 · Open in CIViC	civic
FLT3 ITD AND ( FLT3 D835V OR FLT3 D835Y OR FLT3 Y842C OR FLT3 F691L OR FLT3 Y842H )	Sorafenib	Predictive	D	Supports Resistance	3	submitted	EID12629 In an in-vitro study using an in vitro saturation mutagenesis assay, residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. These mutations… (full text at CIViC) PMID 22504184 · Smith et al., 2012 · Open in CIViC	civic